Led · Series A · Mar 2022

orthobrain provides a total orthodontic practice-growth system combining proprietary digital technology, AI-driven learning systems, and expert orthodontic mentorship to enable general practitioners to deliver orthodontic care. Its offerings include clinical workflow tools, educational resources through orthobrain University, and SimplyClear™, a proprietary clear aligner system launched in 2022 designed for dentists. The company is rolling out an enhanced technology platform to streamline clinical workflows and optimize treatment outcomes. Funding will support team expansion, technology enhancements, marketing, and educational initiatives to expand provider access. orthobrain reports strong commercial traction: revenue grew 145% year-over-year and doctor registrations surged more than 185% since 2023. The company emphasizes enabling case selection, treatment planning, and ongoing orthodontic guidance to drive practice profitability and patient retention. orthobrain is a dental practice growth system that integrates orthodontics into general practices using digital technology, proprietary AI, learning systems and the expertise of orthodontists. Founded in 2016 by Dr. Dan German and based in Cleveland, Ohio, the company positions itself as a proven integration platform for orthodontic services. In July 2022 orthobrain completed a $9M Series A financing. The company intends to use the funds to expand access to quality orthodontic care globally and to scale clinical and education support services. orthobrain also plans to invest in technological solutions and continue innovating its product and service offerings. The description of its core product emphasizes combining technology, AI and orthodontist expertise to drive practice growth.

Participated · Series C · Jan 2015

CoLucid Pharmaceuticals is developing oral lasmiditan for the acute treatment of migraine and an intravenous formulation for use by health care professionals. The company has completed six clinical studies, including a Phase 2b trial treating a single migraine attack in 391 patients and a TQTc study. It plans to use the new funding to advance its Phase 3 program, including the first pivotal study COL MIG-301 “SAMURAI,” for acute migraine treatment. CoLucid emphasizes addressing unmet needs for patients poorly served by current therapies, including those with cardiovascular risk factors who may be unable to take triptans. The company is led by CEO Thomas P. Mathers and is partnered with ILDONG Pharmaceutical under a distribution and supply agreement for lasmiditan in South Korea and Southeast Asia. CoLucid is based in Durham, North Carolina. CoLucid Pharmaceuticals is a privately held biopharmaceutical company based in Research Triangle Park, NC, focused on developing therapies for migraine and other CNS disorders. Its lead program is lasmiditan, a Neurally Acting Anti‑Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of therapies. The company also lists COL-204 for wake promotion and a conjugated stigmine platform that has generated preclinical candidates for chronic pain, Alzheimer’s disease and psychiatric disorders. CoLucid intends to use the financing to advance lasmiditan into Phase 3 development and into pivotal studies planned for 2012. It is interacting with the FDA and is engaged in discussions with potential partners. As of the article, CoLucid has raised $7.5M of a planned $9.5M convertible note financing.

Led · Convertible Note · Jan 2015

Vaxart is a clinical‑stage company developing oral recombinant, temperature‑stable tablet vaccines using a proprietary delivery platform. The platform is suitable for delivering protein antigens used in marketed vaccines and aims to eliminate needles while reducing cold‑chain requirements. The company plans to advance its seasonal influenza tablet vaccine and significantly expand its clinical pipeline beyond influenza. Vaxart expects to conduct phase 1 studies for Ebola and norovirus in 2015; its Ebola tablet vaccine was on schedule to enter the clinic this quarter. Its RSV tablet candidate and a therapeutic tablet vaccine for herpes simplex 2 are currently in preclinical testing. The company reported positive phase 1 safety and immunogenicity results with its H1N1 seasonal influenza tablet vaccine, providing momentum for the planned expansions. Vaxart is a San Francisco biotech developing oral-delivery vaccines formulated to be effective when swallowed in a pill or capsule. Its vaccines incorporate a proprietary adjuvant that boosts the immune response to enable oral administration. The company’s lead product is an oral vaccine for Avian influenza. Vaxart plans to advance that lead candidate through Phase I clinical trials. To support those plans it closed a $12.5M Series B financing. As part of the financing, Richard Markham and Jan Leschly of Care Capital joined Vaxart’s board.

Participated · Equity · Sep 2013

Inotek Pharmaceuticals is focused on developing innovative drugs for eye diseases with a major emphasis on glaucoma; its lead candidate is trabodenoson, a drop‑administered drug currently in Phase 2. Trabodenoson is designed to increase aqueous humor outflow through the eye’s trabecular meshwork, a mechanism differentiated from existing prostaglandins and other approved therapies. Preclinical work and mechanistic studies indicate the drug up‑regulates proteases in the trabecular meshwork to clear proteinaceous blockages and restore outflow. A recently completed multi‑dose Phase 2 monotherapy study showed significant IOP reduction in the range of market‑leading prostaglandins such as latanoprost, and the drug was reported to be safe and well tolerated. Inotek plans to initiate a Phase 2 study later this year to evaluate trabodenoson in combination with latanoprost for patients inadequately controlled on latanoprost alone. Financially, the company closed a $21 million equity financing and concurrently secured $7 million in venture debt to advance ongoing clinical development; the company is located in Lexington, MA. Inotek Pharmaceuticals is a Lexington, Massachusetts-based developer of innovative drug candidates to address significant diseases of the eye. Its lead program is INO-8875, an investigational eye-drop for glaucoma. In an earlier Phase 1/2 trial, INO-8875 was shown to significantly reduce intraocular pressure in glaucoma patients. The company plans to advance INO-8875 into multiple-dose Phase 2 clinical trials. To support that work it closed an $18M preferred stock financing. As part of the round, John Leaman joined Inotek’s board of directors.

Participated · Series C · Jul 2012

Agile Therapeutics, Inc. announced that it secured $45 million in funding from Perceptive Advisors LLC. The company amended the terms of the transaction on March 1, 2021. Following that amendment, the transaction total stood at $45 million. Perceptive Advisors provided an additional $10 million in its fourth tranche close. The financing was completed in multiple tranches, with the fourth tranche bringing in the $10 million contribution. The announcement did not disclose instruments, operating metrics, products, prior rounds, founding year, or location. Agile Therapeutics develops transdermal contraceptive patches and proprietary Skinfusion® delivery technology for stable seven-day drug delivery and adhesion. Its lead product, AG200-15, is a once-weekly contraceptive patch for which Agile filed a New Drug Application (NDA) with the FDA and expects a response in Q1 2013. The company is also developing a progestin-only contraceptive patch, AG890. Agile intends to use the new capital to support pre-launch and launch activities for AG200-15 and to continue development of AG890. The company is led by President and CEO Al Altomari. In conjunction with the financing, Dr. Andrew Schiff of Aisling Capital joined Agile’s board. Agile Therapeutics is a late-stage pharmaceutical company focused on women’s healthcare and developing transdermal contraceptive patches. Its lead product is the AG200-15 contraceptive patch, and the company is also developing a second patch, AG1000. Agile is completing Phase 3 clinical development for AG200-15 and preparing to file for marketing approval. The company plans to advance AG1000 into Phase 2 clinical development and to develop additional pipeline products based on its SKINFUSION™ technology. Agile’s patches are being developed to provide women with a convenient and easy-to-use alternative to their current means of contraception. The company completed a $45M Series B financing to fund these development plans.